

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/810,973 03/25/2004 A. Michael Baca SAL-1003 9641 EXAMINER 7590 03/03/2006 Luis M. Ortiz LAWRENCE JR, FRANK M P.O. Box 4484 ART UNIT PAPER NUMBER Albuquerque, NM 87196 1724

DATE MAILED: 03/03/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		<u></u>	
	Application No.	Applicant(s)	
Office Action Summary	10/810,973	BACA ET AL.	
	Examiner	Art Unit	
	Frank M. Lawrence	1724	
The MAILING DATE of this communication appeared for Reply	opears on the cover sneet with th	ie correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPI WHICHEVER IS LONGER, FROM THE MAILING [- Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICAT .136(a). In no event, however, may a reply b d will apply and will expire SIX (6) MONTHS f tte, cause the application to become ABANDO	ION. be timely filed from the mailing date of this communication. DNED (35 U.S.C. § 133).	
Status			
1) Responsive to communication(s) filed on 17.	January 2006.		
·=	<u>, </u>		
3) Since this application is in condition for allows	•	•	
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D. 11	, 453 O.G. 213.	
Disposition of Claims			
4) ⊠ Claim(s) 1,5,7,8,10,21 and 23-25 is/are pend 4a) Of the above claim(s) is/are withdra 5) ⊠ Claim(s) 7,8,10,21 and 23-25 is/are allowed. 6) ⊠ Claim(s) 1 and 5 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/	awn from consideration.		
Application Papers			
9) The specification is objected to by the Examin	ner		
10)⊠ The drawing(s) filed on <u>25 March 2004</u> is/are: a) accepted or b)⊠ objected to by the Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the corre		- , ,	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	nts have been received. nts have been received in Applic ority documents have been rece au (PCT Rule 17.2(a)).	cation No eived in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	4) Interview Summ Paper No(s)/Ma 3) 5) Notice of Inform 6) Other:		

Application/Control Number: 10/810,973 Page 2

Art Unit: 1724

DETAILED ACTION

Drawings

1. The drawings are objected to because Figures 8A, 9A and 10A are not clear, particularly in the text portions.

2. The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they do not include the following reference sign(s) mentioned in the description: 1050, 1060.

Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

Double Patenting

3. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting

Application/Control Number: 10/810,973

Art Unit: 1724

ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Page 3

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claim 5 is rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-4, 6-14 and 18-22 of U.S. Patent No. 6,919,019 in view of Tribelski '422. The instant claim differs from the patented claims because the instant claims recite the treatment of a fluid in a laboratory or airplane recirculation system instead of water. One having ordinary skill in the art would realize that the recited structure is inherently capable of conducting any type of fluid. Tribelski teaches a laser UV treatment system that can be used to treat either liquids or gases and in a laboratory gas supply system and in air conditioning systems (col. 4, lines 33-50, col. 16, lines 38-60).

Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 6. Claims 1 and 5 are rejected under 35 U.S.C. 102(e) as being anticipated by Tribelski (6,468,433).
- 7. Tribelski '433 teaches a system for killing microorganisms in an air conduit or water treatment system such as a dialysis unit by deactivating DNA in the fluid, comprising a chamber with an entry point and exit point for receiving the fluid and an ultraviolet laser coupled to the

Application/Control Number: 10/810,973 Page 4

Art Unit: 1724

chamber with fiber optics for applying UV light at between 220nm-2400 nm (see figures, col. 1, lines 46-56, col. 7, lines 41-46, col. 13, lines 8-23, col. 15, lines 4-11, col. 16, lines 38-51, col. 21, lines 21-32, col. 24, lines 35-58, claim 16). Also, it is disclosed that UV light at between 250-280 nm is optimum for deactivating DNA sequences (col. 6, lines 11-31). The system can be used in air conditioning systems for hospitals and in gas supplies for laboratories or clinics (col. 4, lines 33-50, col. 16, lines 38-60).

Allowable Subject Matter

- 8. Claims 7, 8, 10, 21 and 23-25 are allowed.
- 9. The following is an examiner's statement of reasons for allowance: Independent claim 7 has been amended by applicant to include the limitation that the treatment areas comprise a housing having an entry point for receiving fluid into the treatment area and an exit point for allowing treated fluid to continue moving towards its point of use and at least one UV semiconductor laser light source coupled to the housing for providing UV light into fluid containing biological microorganisms, which is not disclosed or suggested in the prior art of record in combination with the other recited elements.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Response to Arguments

10. Applicant's arguments filed January 17, 2006 have been fully considered but they are not persuasive. Applicant has not presented any arguments as to why claims 1 and 5 distinguish

Art Unit: 1724

over the prior art. The rejection over Tribelski '433 is maintained because the patent discloses use in a laboratory environment.

Conclusion

11. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank M. Lawrence whose telephone number is 571-272-1161. The examiner can normally be reached on Mon-Thurs 7:30-6:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Duane Smith can be reached on 571-272-1166. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/810,973

Art Unit: 1724

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Frank M. Lawrence Primary Examiner Art Unit 1724 Page 6

fl

Trade faurence 3-1-06